| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| August 15, 2014 | CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 4,000 | $3.12 | 74,521 | |
| June 20, 2014 | Director, CEO | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 15,000 | -- | 77,521 | |
| June 20, 2014 | Director, CEO | Form 4/A | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 3,000 | $3.50 | 74,521 | |
| June 20, 2014 | Director, CEO | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 140,556 | -- | 443,885 | |
| February 11, 2014 | Director, CEO | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 44,444 | -- | 303,329 | |
| June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 400 | $4.38 | 27,067 | |
| June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 300 | $4.39 | 27,367 | |
| June 16, 2008 | Director, President & CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 1,800 | $4.40 | 29,167 | |
| March 14, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4/A | Open market or private purchase of non-derivative or derivative security | 200 | $4.05 | 200 | |
| March 14, 2006 | VP - Clin. Dev. & Med. Affairs | Form 4/A | Open market or private purchase of non-derivative or derivative security | 800 | $4.05 | 1,000 | |
| November 17, 2005 | EVP, CFO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 21,300 | $0.29 | 231,667 | |
| November 16, 2005 | EVP, CFO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 3,700 | $0.29 | 210,367 | |
| November 15, 2005 | VP of Operations | Form 4/A | Open market or private purchase of non-derivative or derivative security | 20,000 | $0.31 | 30,000 | |
| November 14, 2005 | President, CEO | Form 4/A | Open market or private purchase of non-derivative or derivative security | 76,645 | $0.33 | 139,145 | |
| May 13, 2024 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 112,500 | -- | 126,666 | |
| March 15, 2024 | Chief Scientific Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 110,688 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,500 | -- | 19,930 | |
| March 15, 2024 | CFO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 25,000 | -- | 120,950 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,500 | -- | 9,167 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,500 | -- | 33,599 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,500 | -- | 14,166 | |
| March 15, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,500 | -- | 14,166 | |
| March 15, 2024 | Director, Executive Chairman of Board | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 12,500 | -- | 228,346 | |
| December 7, 2023 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,000 | -- | 20,000 | |
| December 7, 2023 | Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,000 | -- | 80,000 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.
